LeMaitre Vascular (NASDAQ:LMAT) Issues Q1 2025 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its first quarter 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.480-0.530 for the period, compared to the consensus estimate of 0.510. The company issued revenue guidance of $56.7 million-$58.7 million, compared to the consensus revenue estimate of $58.1 million. LeMaitre Vascular also updated its FY 2025 guidance to 2.150-2.320 EPS.

LeMaitre Vascular Stock Performance

LMAT traded down $8.06 on Friday, hitting $91.85. 442,236 shares of the company were exchanged, compared to its average volume of 137,287. The firm has a fifty day simple moving average of $96.89 and a two-hundred day simple moving average of $94.73. The stock has a market capitalization of $2.07 billion, a PE ratio of 50.19, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96. LeMaitre Vascular has a 12 month low of $62.39 and a 12 month high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $55.81 million for the quarter, compared to the consensus estimate of $55.99 million. On average, equities analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on LMAT shares. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday. Wells Fargo & Company began coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an “equal weight” rating and a $95.00 price target on the stock. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Oppenheimer downgraded shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday. Finally, Lake Street Capital raised their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $95.25.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.